Get the Daily Brief
Latest Biotech News
Aurora launches to scale bespoke CRISPR therapies under new FDA pathway
Aurora Therapeutics launched with seed funding and a leadership team tied to the ‘Baby KJ’ personalized CRISPR success story, aiming to develop grouped, customizable gene‑editing therapies that...
GSK licenses Noetik’s cancer foundation models in $50m pact
GSK committed $50 million upfront to license Noetik Discovery’s foundation AI models trained on large spatial biology datasets for non‑small cell lung and colorectal cancer research. The...
EpiBiologics raises $107m to ready protein‑degrading antibody for clinic
EpiBiologics closed a $107 million Series B to advance EPI‑326, a bispecific antibody designed to degrade tumor EGFR via targeted lysosomal routing, into first‑in‑human studies. The Bay Area...
Medipost raises $140m to bring Korean stem‑cell therapy to US and Japan
Medipost secured $140 million to support commercialization and regulatory filings for its allogeneic stem cell therapy in the U.S. and Japan. The Seoul‑area company will use the funds to expand...
Lilly pays $1.2B for Ventyx — buys NLRP3 inflammation program
Eli Lilly agreed to acquire Ventyx Biosciences for about $1.2 billion in cash, closing a deal that transfers clinical-stage NLRP3 inhibitor programs into Lilly’s pipeline. The transaction,...
Merck in talks to buy Revolution Medicines – $28–32bn reported
Merck reportedly entered talks to acquire Revolution Medicines in a deal valued between $28 billion and $32 billion, according to media reports citing unnamed sources. The discussions center on...
Aktis upsized IPO raises $318M — radiopharma player hits Nasdaq
Radiopharmaceutical developer Aktis Oncology priced an upsized initial public offering that raised roughly $318 million in gross proceeds, with Eli Lilly taking a $100 million stake as part of the...
Parabilis lands $305M Series F — pushes peptide platform toward clinic
Parabilis Medicines closed a $305 million Series F round to accelerate its Helicon peptide platform and advance lead candidate zolucatetide toward later‑stage testing. The financing was led by RA...
EpiBiologics raises $107M — protein‑degrader antibody nears human testing
EpiBiologics secured $107 million in a Series B round led by GV and J&J’s venture arm to push its antibody‑based protein degraders (EpiTACs) into first‑in‑human studies. The Bay Area startup will...
Immuneering’s MEK pill posts strong survival update — 64% at 12 months
Immuneering reported updated phase 2a data showing a 64% overall survival rate at one year for atebimetinib, its oral MEK inhibitor, combined with modified gemcitabine/nab‑paclitaxel as first‑line...
Cellares, City of Hope to automate CAR‑T manufacturing for glioblastoma
Cellares and City of Hope signed a collaboration to evaluate automated, high‑throughput manufacturing and QC for a CAR‑T program targeting glioblastoma multiforme. City of Hope will test Cellares’...
OpenAI launches ChatGPT for Healthcare — enterprise push into hospitals
OpenAI introduced ChatGPT for Healthcare, an enterprise offering to integrate the ChatGPT platform into hospital and health‑system workflows. The product is positioned to support clinical...
Analysis: FDA staff cuts mostly didn’t slow new‑drug reviews
An analysis found that despite sweeping staff departures and leadership churn at the FDA in 2025, reviewers met the majority of user‑fee commitments for new drug reviews and approvals. The report...
Guardant’s Shield nabs Tricare coverage — expands military access
Guardant Health said Tricare will cover its Shield blood‑based colorectal cancer screening test, making Shield available with no copay to active‑duty service members and their families aged 45 and...
Lilly shells out $1.2B for Ventyx – oral NLRP3 bet
Eli Lilly agreed to acquire San Diego‑based Ventyx Biosciences for roughly $1.2 billion in cash, buying a mid‑stage oral NLRP3 inhibitor program the buyer calls strategically complementary to its...
Aktis prices IPO at $18 – $318M to advance radiopharma pipeline
Aktis Oncology priced an initial public offering that raised about $318 million, marking the first US biotech IPO of 2026 and signaling renewed public‑market appetite for radiopharmaceuticals. The...
Mediar closes $76M Series B: anti‑fibrotics advance to clinic
Mediar Therapeutics closed an oversubscribed $76 million Series B co‑led by ICG Life Sciences and Amplitude Ventures to accelerate clinical development of multiple anti‑fibrotic antibodies. The...
Parabilis nets $305M Series F – corkscrew peptides eye late‑stage push
Parabilis Medicines raised $305 million in an oversubscribed Series F to advance its Helicon‑derived corkscrew peptide platform and lead candidate zolucatetide toward later‑stage studies. The...
EpiBiologics raises $107M to push protein‑degrading antibody into clinic
EpiBiologics closed a $107 million Series B led by GV and Johnson & Johnson’s venture arm to advance its EpiTAC platform and lead bispecific degrader EPI‑326 into first‑in‑human studies. The Bay...
Immuneering’s MEK candidate posts strong updated survival in first‑line pancreatic study
Immuneering reported updated phase IIa data showing a 64% overall survival rate at 12 months for atebimetinib combined with modified gemcitabine/nab‑paclitaxel in first‑line pancreatic cancer,...